DUBLIN–(BUSINESS WIRE)–The “Generalized Myasthenia Gravis (gMG) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.
This ‘Generalized Myasthenia Gravis (gMG)- Epidemiology Forecast – 2032’ report delivers an in-depth understanding of Generalized Myasthenia Gravis (gMG) historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Generalized Myasthenia Gravis (gMG) Epidemiology
The Generalized Myasthenia Gravis (gMG) epidemiology division provides insights about the historical and prevalent patient pool, along with the forecasted trend for all the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.
Key Findings
The total diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG) patients in the 7MM are increasing during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Generalized Myasthenia Gravis (gMG) epidemiology segmented as the total diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG), gender-specific cases of Generalized Myasthenia Gravis (gMG), and antibodies-specific cases of Generalized Myasthenia Gravis (gMG).
The report includes the diagnosed prevalent cases scenario of Generalized Myasthenia Gravis (gMG) in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country-wise Generalized Myasthenia Gravis (gMG) Epidemiology
- The diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG) associated in the 7MM countries were approximately 116,100 in 2021.
- As per the estimates, the United States has the largest diagnosed prevalent population of Generalized Myasthenia Gravis (gMG)
- Among the EU5 countries, Germany had the highest diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG), followed by the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent cases with around 8,800 cases in 2021.
Scope of the Report
- The Generalized Myasthenia Gravis (gMG) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
- The Generalized Myasthenia Gravis (gMG) Epidemiology Report and Model provide an overview of Generalized Myasthenia Gravis (gMG)’ risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into Generalized Myasthenia Gravis (gMG)’ historical and forecasted patient pool in the seven major markets covering the United States, the EU-5 (Germany, Spain, France, Italy, UK), and Japan.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis (gMG).
- The report provides the segmentation of the Generalized Myasthenia Gravis (gMG) epidemiology by the Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
- The report provides the Generalized Myasthenia Gravis (gMG) epidemiology segmentation by gender-specific cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
- The report provides the Generalized Myasthenia Gravis (gMG) epidemiology segmentation by antibodies-specific cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
Report Highlights
- 11-year Forecast of Generalized Myasthenia Gravis (gMG) epidemiology
- 7MM Coverage
- Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG)
- Gender-specific cases of Generalized Myasthenia Gravis (gMG)
- Antibodies-specific Cases of Generalized Myasthenia Gravis (gMG)
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Generalized Myasthenia Gravis (gMG) Market Overview at a Glance
3.1. Patient Share (%) Distribution of Generalized Myasthenia Gravis (gMG) in 2019
3.2. Patient Share (%) Distribution of Generalized Myasthenia Gravis (gMG) in 2032
4. Executive Summary of Myasthenia Gravis (MG)
5. Disease Background and Overview
5.1. Introduction
5.2. Types of MG
5.3. Clinical Classification of MG
5.4. Etiology
5.5. Risk Factors
5.6. Clinical Manifestations
5.7. Pathophysiology
5.8. Biomarkers
5.9. Diagnosis
5.9.1. Diagnostic guidelines
5.10. Differential Diagnosis
5.11. Treatment Guidelines
5.11.1. International consensus guidance for management of myasthenia gravis
5.11.2. Italian recommendations to treat myasthenia gravis
5.11.3. German Neurological Society Guidelines for myasthenia gravis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Diagnosed Prevalent Population of Generalized Myasthenia Gravis (gMG)
6.3. Assumptions and Rationale
6.3.1. Assumptions and Rationale
6.4. The United States
6.4.1. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the United States
6.4.2. Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in the United States
6.4.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in the United States
6.5. EU-5
6.6. Japan
7. Patient Journey
8. KOL Views
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/5aj8ud
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
